Randomized pilot study on probiotic effects on recurrent candidiasis in oral lichen planus patients

Keller, Mette Kirstine; Kragelund, Camilla

doi:10.1111/odi.12858

Cited by 27 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty‐two white patients with symptomatic OLP completed the study: 12 females and 10 males with a median age of 67 and age range between 27 and 79 years (for further demographic details, see Keller & Kragelund, ).…”

Section: Resultsmentioning

confidence: 99%

“…Diagnosis of OC was based on clinical findings or concomitant symptoms of OC and one or more Candida hyphae in cytosmear (for further details, see Keller & Kragelund, ; Kragelund, Kieffer‐Kristensen, Reibel, & Bennett, ). Depending on diagnosis, all patients were initially treated with the current conventional treatment regimens at the clinic: OC was treated with nystatin ointment for 4 weeks and no OC was treated with topical steroid (Synalar ® , fluocinolone acetonide gel 0.025%) for 3 weeks (for further details, see Keller & Kragelund, ). Additionally, patients were randomly allocated into either the probiotic group receiving chewable tablets with two strains of L. reuteri (DSM 17938 and ATCC PTA 5289) or the placebo group receiving similar chewable tablets but without probiotic bacteria.…”

Section: Methodsmentioning

confidence: 99%

“…Our group initiated to our knowledge the first double‐blinded, randomized, placebo‐controlled probiotic intervention pilot study in OLP patients in order to re‐establish the balance of the oral microbiome (Keller & Kragelund, ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The oral microbiome in oral lichen planus during a 1‐year randomized clinical trial

Kragelund

Keller

2018

Oral Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The oral microbiome in oral lichen planus during a 1‐year randomized clinical trial

Kragelund

Keller

2018

Oral Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…So, despite an incomplete understanding of the healthy gut microbiome and the pathogenesis of ulcerative colitis, microbiome studies have enabled researchers to formulate and test hypotheses that have produced promising interventions. The same approach has been tested to a limited extent for its potential to influence oral health and reduce counts of Streptococcus mutans (Seminario‐Amez, Lopez‐Lopez, Estrugo‐Devesa, Ayuso‐Montero, & Jane‐Salas, ) and Candida (Keller & Kragelund, ) with variable results.…”

Section: Discussionmentioning

confidence: 99%

World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders

et al. 2019

View full text Add to dashboard Cite

Objective The World Workshop on Oral Medicine VII chose the oral microbiome as a focus area. Part 1 presents the methodological state of the science for oral microbiome studies. Part 2 was guided by the question: What is currently known about the microbiome associated with oral squamous cell carcinoma and potentially malignant disorders of the oral mucosa? Materials and Methods A scoping review methodology was followed to identify and analyse relevant studies on the composition and potential functions of the oral microbiota using high‐throughput sequencing techniques. The authors performed searches in PubMed and EMBASE. After removal of duplicates, a total of 239 potentially studies were identified. Results Twenty‐three studies on oral squamous cell carcinoma, two on oral leukoplakia and four on oral lichen planus were included with substantial differences in diagnostic criteria, sample type, region sequenced and sequencing method utilised. The majority of studies focused on bacterial identification and recorded statistically significant differences in the oral microbiota associated with health and disease. However, even when comparing studies of similar methodology, the microbial differences between health and disease varied considerably. No consensus on the composition of the microbiomes associated with these conditions on genus and species level could be obtained. Six studies on oral squamous cell carcinoma had included in silico predicted microbial functions (genes and/or pathways) and found some similarities between the studies. Conclusions Attempts to reveal the microbiome associated with oral mucosal diseases are still in its infancy, and the studies demonstrate significant clinical and methodological heterogeneity across disease categories. The immense richness and diversity of the microbiota clearly illustrate that there is a need for additional methodologically comparable studies utilising deep sequencing approaches in significant cohorts of subjects together with functional analyses. Our hope is that following the recipe as outlined in our preceding companion paper, that is Part 1, will enhance achieving this in the future and elucidate the role of the oral microbiome in oral squamous cell carcinoma and potentially malignant disorders of the oral mucosa.

show abstract

“…Both the control group and the probiotic group had a significant decrease in Candida detection rate at 4 weeks, and while probiotics had a significantly lower detection rate compared to controls, this difference did not translate into clinical effect; there was no significant difference in visual analogue scale scores or hyperaemia between the two groups at 4 weeks (Li et al, ). Similarly, after conventional treatment for oral lichen planus with fluocinolone acetonide gel or oral candidiasis with nystatin, there was no significant difference in oral candidiasis recurrence or need for symptomatic treatment in patients receiving lozenges containing L. reuteri compared to controls (Keller & Kragelund, ).…”

Section: Probiotics and Oral Candidiasismentioning

confidence: 98%

Probiotics for oral and vulvovaginal candidiasis: A review

Shenoy

Gottlieb

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Dermatologists commonly prescribe medications such as antibiotics and corticosteroids that can increase the risk for candidiasis. Though conventional antifungals are often effective against candidiasis, they are not without side effects and species of Candida are gaining resistance. Probiotics help treat conditions such as post‐antibiotic diarrhea and infectious diarrhea, and thus have the potential to help with Candida infections, as well. For this reason, we provide an overview of therapies prescribed in dermatology that may increase the risk for candidiasis, and we review the literature on whether probiotics are useful in the treatment and prevention of oral and vulvovaginal candidiasis to help dermatologists treating the condition be better informed about their supplemental use with conventional antifungals.

show abstract

Randomized pilot study on probiotic effects on recurrent candidiasis in oral lichen planus patients

Abstract: Probiotic intervention did not reduce recurrent OC or Candida count/carriage, but the study experienced recruitment problems, which may have influenced results.

Cited by 27 publications

References 26 publications

The oral microbiome in oral lichen planus during a 1‐year randomized clinical trial

The oral microbiome in oral lichen planus during a 1‐year randomized clinical trial

World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders

Probiotics for oral and vulvovaginal candidiasis: A review

Contact Info

Product

Resources

About